Management of acute central retinal artery occlusion.

Author(s): Chen CS, Lee AW

Affiliation(s): CS Chen is a Consultant Neuro-ophthalmologist in the Department of Ophthalmology and AW Lee is a Consultant Cerebrovascular Neurologist in the Department of Neurology, Flinders Medical Centre, Flinders University, Bedford Park, South Australia, Australia.

Publication date & source: 2008-06-10, Nat Clin Pract Neurol., [Epub ahead of print]

Publication type:

Central retinal artery occlusion (CRAO) is considered to be an acute stroke of the eye that results in profound visual loss. Spontaneous recovery rates are poor. Most CRAOs are caused by thromboembolism in the central retinal artery. Current standard therapies for CRAO that aim to restore perfusion to the retina and optic nerve head have not been shown to alter the natural course of the disease. Thrombolytic therapy for acute management of CRAO has shown promise in nonrandomized studies with regard to improving visual outcomes. A randomized controlled trial will be required to confirm the efficacy of thrombolytic therapy before it can be recommended for use in CRAO in daily clinical practice.